Therefore, targeting highly abundant immunosuppressive cytokines such as IL-10 and TGF-β in the tumor microenvironment significantly helps to reverse immunosuppression, improving the efficacy of conventional cancer therapies, activating antitumor immunity, and controlling tumorigenesis. Here, TGFB1 is linked to neoplasm.